Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Abstract
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk. RESULTS: A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or death, 0.82; P=0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 patients (63%), respectively. Treatment-related adverse events leading to discontinuation occurred in 22% and 12% of the patients in the respective groups. CONCLUSIONS: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- New England Journal of Medicine
- Topic
- Renal cell carcinoma treatment
- Field
- Medicine
- Canadian institutions
- BC Cancer AgencyUniversity Hospital Foundation
- Funders
- Foundation MedicineKite PharmaGenentechAstellas PharmaEisaiJounce TherapeuticsTakeda OncologyMirati TherapeuticsAcceleronClovis OncologyBioMarin PharmaceuticalMylanCelldex TherapeuticsTaiho PharmaceuticalHorizon PharmaIpsenArray BioPharmaBayer HealthCareExelixisSanofiMemorial Sloan-Kettering Cancer CenterGlaxoSmithKlineAmgenINOVIO PharmaceuticalsDaiichi Sankyo EuropeNational Cancer InstituteLEO PharmaIntuitive SurgicalPfizerEUSA PharmaAstraZenecaOno PharmaceuticalEli Lilly and CompanyBristol-Myers Squibb
- Keywords
- IpilimumabSunitinibNivolumabRenal cell carcinomaMedicineInternal medicineOncologyCancer researchUrologyImmunotherapyCancer
- Has abstract in OpenAlex
- yes